Are you looking for a potential new celiac disease treatment?
The LILY Study is a phase 1 celiac disease study that will measure the effectiveness of the study medication, DONQ52, at targeting an immune complex known to cause celiac disease symptoms.
There is no gluten challenge in this study. You may be compensated for time and travel.
- You are 18-65 years old
- You have celiac disease
- You are already on a gluten-free diet
- You have had a diagnostic biopsy
- Other requirements will apply.
Study Site Locations:
- Multisite (US)
If you’re interested in the study, think you may qualify, or want to find a study site location near you, visit www.celiacdiseasestudy.com.